Discovery of Biofilm Inhibitors from the Microbiota of Marine Egg Masses.
Lois KyeiKarla PiedlCarla MenegattiEleanor M MillerEmily MeversPublished in: Journal of natural products (2024)
Biofilms commonly develop in immunocompromised patients, which leads to persistent infections that are difficult to treat. In the biofilm state, bacteria are protected against both antibiotics and the host's immune system; currently, there are no therapeutics that target biofilms. In this study, we screened a chemical fraction library representing the natural product capacity of the microbiota of marine egg masses, namely, the moon snail egg collars. This led to the identification of active fractions targeting both Pseudomonas aeruginosa and Staphylococcus aureus biofilms. Subsequent analysis revealed that a subset of these fractions were capable of eradicating preformed biofilms, all against S. aureus . Bioassay-guided isolation led us to identify pseudochelin A, a known siderophore, as a S. aureus biofilm inhibitor with an IC 50 of 88.5 μM. Mass spectrometry-based metabolomic analyses revealed widespread production of pseudochelin A among fractions possessing S. aureus antibiofilm properties. In addition, a key biosynthetic gene involved in producing pseudochelin A was detected on 30% of the moon snail egg collars and pseudochelin A is capable of inhibiting the formation of biofilms (IC 50 50.6 μM) produced by ecologically relevant bacterial strains. We propose that pseudochelin A may have a role in shaping the microbiome or protecting the egg collars from microbiofouling.
Keyphrases
- candida albicans
- pseudomonas aeruginosa
- biofilm formation
- staphylococcus aureus
- mass spectrometry
- epithelial mesenchymal transition
- end stage renal disease
- cystic fibrosis
- chronic kidney disease
- small molecule
- escherichia coli
- newly diagnosed
- ejection fraction
- single cell
- signaling pathway
- genome wide
- contrast enhanced
- prognostic factors
- magnetic resonance imaging
- ultrasound guided
- magnetic resonance
- multidrug resistant
- cancer therapy
- gas chromatography
- drug resistant
- fine needle aspiration
- light emitting
- patient reported
- genome wide identification